You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 A Weibull accelerated failure time models of PFS

From: Being treated in higher volume hospitals leads to longer progression-free survival for epithelial ovarian carcinoma patients in the Rhone-Alpes region of France

  Main analysis Sensitivity analysis
  Threshold = 12 Threshold = 5 Threshold = 8
  Coefficient σ Coefficient σ Coefficient σ
High-volume hospital 0.41*** 0.136 0.21 0.141 0.33*** 0.124
Age − 0.01** 0.005 − 0.01** 0.005 − 0.01** 0.005
Cancer history − 0.20 0.154 − v0.24 0.157 − 0.24 0.154
Ascites − 0.32** 0.145 0.32** 0.149 − 0.34** 0.149
Neoadjuvant chemotherapy − 0.30** 0.132 − 0.26* 0.135 − 0.29** 0.134
Histology:
 - HGSC Ref   Ref   Ref  
 - LGSC 0.23 0.490 0.28 0.499 0.30 0.495
 - Mucinous 0.14 0.453 0.14 0.467 0.16 0.460
 - Endometrioid 0.15 0.259 0.27 0.256 0.26 0.258
 - Clear cell − 0.01 0.279 − 0.11 0.286 − 0.16 0.284
 - Unknown − 0.19 0.209 − 0.09 0.211 − 0.16 0.209
FIGO Stage:
 - I Ref   Ref   Ref  
 - II − 0.42 0.371 − 0.34 0.375 − 0.35 0.370
 - III − 0.58** 0.285 − 0.59** 0.292 − 0.58** 0.290
 - IV − 0.82** 0.319 − 0.85*** 0.328 − 0.79*** 0.324
Tumor Grade:
 - 1 Ref   Ref   Ref  
 - 2 − 0.03 0.420 − 0.09 0.428 − 0.09 0.423
 - 3 − 0.01 0.416 0.06 0.424 0.05 0.420
Intercept 4.77*** 0.615 4.60*** 0.634 4.65*** 0.626
  1. σ: standard deviation / Ref: modality in reference
  2. HGSC High-Grade Serous Carcinoma, LGSC Low-Grade Serous Carcinoma
  3. *, **, ***: significant at 10%, 5%, and 1%, respectively